[Clinical application of undercarboxylated osteocalcin]
Toshiyuki Yasui1, Masayo Yamada, Minoru Irahara
1The University of Tokushima Graduate School, Institutes of Health Biosciences, Department of Obstetrics and Gynecology.
Clinical Calcium
|November 6, 2007
Summary
Undercarboxylated osteocalcin (ucOC), a vitamin K (VK) status marker, is higher in perimenopausal women and linked to hormone levels. Hormone therapy impacts ucOC, with oral conjugated equine estrogen showing a stronger effect than transdermal estradiol.
Area of Science:
- Biochemistry
- Endocrinology
- Nutritional Science
Context:
- Serum undercarboxylated osteocalcin (ucOC) is a sensitive indicator of vitamin K (VK) status.
- Perimenopausal women exhibit significantly higher serum ucOC concentrations compared to premenopausal women.
- Serum ucOC levels correlate with follicle-stimulating hormone (FSH) and estradiol concentrations.
Purpose:
- To investigate the relationship between vitamin K status, hormonal changes, and undercarboxylated osteocalcin (ucOC) in women.
- To evaluate the impact of hormone therapy (HT) on serum ucOC concentrations.
Summary:
- Serum ucOC concentration increases notably after bilateral oophorectomy.
- Daily hormone therapy (HT) demonstrates a more significant effect on ucOC levels than alternate-day HT.
- Oral conjugated equine estrogen (CEE) in HT may decrease ucOC by promoting VK-dependent carboxylation, potentially influenced by increased triglycerides (TG).
- Transdermal estradiol-based HT has a weaker effect on ucOC compared to oral CEE.
Impact:
- Provides insights into the interplay between hormonal status, vitamin K, and bone metabolism markers in women.
- Informs clinical management regarding hormone therapy choices and their influence on vitamin K status.
- Highlights the importance of monitoring ucOC in perimenopausal women and those undergoing hormone replacement therapy.
